BRNS
Barinthus Biotherapeutics plc.Company with tickers: BRNS
CIK
1828185
CUSIP
91864C107
Shares Outstanding
40,848,893
13F Activity (30d)
14 filings
13 filers
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | — | ||||
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $6,121,000 | USD | 2026-03-31 | 10-Q | 2026-04-30 |
| Research & Development | $3,593,000 | USD | 2026-03-31 | 10-Q | 2026-04-30 |
| Operating Income | $-6,075,000 | USD | 2026-03-31 | 10-Q | 2026-04-30 |
| Net Income | $-5,531,000 | USD | 2026-03-31 | 10-Q | 2026-04-30 |
| EPS (Basic) | $-0.14 | USD/shares | 2026-03-31 | 10-Q | 2026-04-30 |
| EPS (Diluted) | $-0.14 | USD/shares | 2026-03-31 | 10-Q | 2026-04-30 |